Article
Generic versions of oxybutynin gain approval for OAB
The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder.
The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder. Mylan Laboratories received final approval for 5- and 10-mg extended-release tablets, and IMPAX Laboratories received approval for 15-mg extended-release tablets. Both companies said the products would be launched immediately.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
RX Review: Redefining treatment for LG-IR-NMIBC
Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
Understanding pediatric urologist burnout
Urologist finds Rezum AE rates in larger prostates “reassuring”
Men’s Health Awareness Month: A new era of patient engagement
The Logistical Challenges in ccRCC Treatment
Related Content
